Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798
View directory record Official record
Conditions
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions
Aflibercept, foselutoclax
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation

NCT01879098
View directory record Official record
Conditions
Healthy
Interventions
Probiotic: Bacillus subtilis, Lactobacillus plantarum, Bifidobacterium animalis, Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
35 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 23, 2026, 3:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

NCT05655221
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
B1344, Placebo
Drug · Other
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1 Interventional

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

NCT05031806
View directory record Official record
Conditions
Dry Eye Disease
Interventions
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

NCT00921804
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT06100952
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
Combination Product
Lead sponsor
Epion Therapeutics
Industry
Eligibility
8 Years to 45 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

NCT00071409
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
INGAP-Peptide, placebo
Drug
Lead sponsor
Exsulin Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
10
States / cities
Irvine, California • San Diego, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 3 Interventional

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00256932
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
137
States / cities
Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 23, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

NCT05631093
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ART, DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

NCT04633447
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Kansas City, Kansas • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

NCT01147809
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag olamine, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
33
States / cities
Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 23, 2026, 3:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Obesity Through Play Among Toddlers: Tiny Steps to Health (TSHS) Study

NCT06918821
View directory record Official record
Conditions
Childhood Obesity
Interventions
Healthy Toddler Parent Group (HTPG), Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) Playgroup
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Months to 36 Months
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

OTO-313 in Subjects With Unilateral Subjective Tinnitus

NCT04829214
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
OTO-313, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Fresno, California • Torrance, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

NCT01520987
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIA 9-1067, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 23, 2026, 3:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

NCT01251406
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Placebo, rhNRG-1 Dose 1, rhNRG-1 Dose 2
Drug
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865
View directory record Official record
Conditions
Psoriasis
Interventions
JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

NCT01903265
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL 2.8mg, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 23, 2026, 3:34 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 23, 2026, 3:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Coenzyme Q10 in Older Athletes Treated With Statin Medications

NCT01026311
View directory record Official record
Conditions
Muscle Weakness, Myalgia, Side Effects of Statins
Interventions
Coenzyme q 10, placebo
Drug
Lead sponsor
Richard Deichmann, MD
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 23, 2026, 3:34 PM EDT